Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

80
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
80
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

82
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
82
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

76
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
76
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

109
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
109
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.5K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment-associated phenotype switching between psoriasis and atopic dermatitis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Complete clearance of high-impact sites with risankizumab in patients with psoriasis: a 2-year real-world retrospective multicenter cohort study.

The Journal of dermatological treatment·2026
Same author

Quality of life impairment in vitiligo: A comprehensive review of psychosocial and clinical determinants.

The Journal of international medical research·2026
Same author

Icotrokinra: An Oral Interleukin-23 Receptor Antagonist Peptide for the Treatment of Psoriasis.

American journal of clinical dermatology·2026
Same author

High-Dose, Extended Half-Life IL-23 Inhibitors: the Next Big Step in Psoriasis Care?

Dermatology and therapy·2026
Same author

Perspectives and Real-World Clinical Practice of Portuguese Dermatologists on Biologic Dose Spacing in Psoriasis: Results from a Nationwide Survey.

Dermatology and therapy·2026
Same journal

Molluscum Contagiosum Treatments in Children: A Systematic Review with Network Meta-Analysis.

Paediatric drugs·2026
Same journal

Real-World Systemic Treatment Patterns and Outcomes of Children With Severe Alopecia Areata: A French Nationwide Study (ESTAPED ohort).

Paediatric drugs·2026
Same journal

Epinephrine Underuse for Anaphylaxis in Infants and Toddlers: A Practical Review for Pediatricians.

Paediatric drugs·2026
Same journal

Risks of Undertreatment and Overtreatment in Pediatric Inflammatory Bowel Disease: Navigating the Balance.

Paediatric drugs·2026
Same journal

Discontinuing Colchicine in Pediatric Familial Mediterranean Fever: Real-Life Experience from a Long-Term Follow-Up Cohort.

Paediatric drugs·2026
Same journal

Sirolimus Therapy and Dyslipidemia in Neonates and Infants: A Retrospective Cohort and Pharmacovigilance Analysis.

Paediatric drugs·2026
See all related articles

Related Experiment Video

Updated: Nov 10, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.2K

Targeted Therapy for Pediatric Psoriasis.

Miguel Nogueira1, Amy S Paller2, Tiago Torres3,4

  • 1Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal.

Paediatric Drugs
|April 3, 2021
PubMed
Summary
This summary is machine-generated.

Biological drugs are increasingly effective for treating pediatric psoriasis. Recent approvals and ongoing trials offer new hope for managing this inflammatory skin condition in children.

More Related Videos

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
05:08

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

6.4K
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

13.0K

Related Experiment Videos

Last Updated: Nov 10, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.2K
Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
05:08

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

6.4K
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

13.0K

Area of Science:

  • Dermatology
  • Immunology
  • Pediatric Medicine

Background:

  • Psoriasis is a chronic, immune-mediated inflammatory skin disease affecting all age groups.
  • Biological therapies have revolutionized adult psoriasis treatment, but pediatric application faced historical limitations due to efficacy and safety uncertainties.

Purpose of the Study:

  • To review the current landscape of biological agents for pediatric psoriasis treatment.
  • To highlight recent regulatory approvals and ongoing clinical research in this area.

Main Methods:

  • Review of European Medicines Agency (EMA) and US Food and Drug Administration (FDA) approvals for pediatric psoriasis biologics.
  • Summary of ongoing clinical trials investigating targeted therapies, including TNF inhibitors, IL-17, IL-23 inhibitors, and PDE4 inhibitors.

Main Results:

  • Five biological agents (etanercept, adalimumab, ustekinumab, secukinumab, ixekizumab) are approved by EMA for pediatric psoriasis.
  • Three agents (etanercept, ustekinumab, ixekizumab) have received US FDA approval for pediatric psoriasis.
  • Seventeen clinical trials are underway for various targeted therapies in pediatric patients.

Conclusions:

  • The use of biological agents for pediatric psoriasis has significantly advanced, with several drugs now approved.
  • Ongoing research is crucial for expanding treatment options and improving the management of psoriasis in children.